Stargardt Disease clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for

  • ALK-001 on Stargardt Disease

    open to eligible people ages 8-70

    The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD

    at UCLA

  • Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).

    at UCLA

Our lead scientists for Stargardt Disease research studies include .

Last updated: